APA (7th ed.) Citation

Gómez-Casares, M. T., Hernández-Boluda, J. C., Jiménez-Velasco, A., Martínez-López, J., Ferrario, M. G., Gozalbo, I., . . . Subirá, R. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. Columbia Data Analytics, LLC.

Chicago Style (17th ed.) Citation

Gómez-Casares, María Teresa, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz, and Rudi Subirá. Cost-effectiveness of Ruxolitinib Vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. Columbia Data Analytics, LLC.

MLA (9th ed.) Citation

Gómez-Casares, María Teresa, et al. Cost-effectiveness of Ruxolitinib Vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. Columbia Data Analytics, LLC.